David Roife

David Roife

Auto-generated profile, based on publicly available information

David Roife

Departments of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2021 in Molecular Metabolism
Verified
Journal Article
Open access
YCYIHUI CHEN
YIHUI CHEN
MCMichela Capello
Michela Capello
MPMayrim V. Rios Perez
Mayrim V. Rios Perez
JVJody Vykoukal
Jody Vykoukal
DRDavid Roife
David Roife
JFJohannes Fahrmann
Johannes Fahrmann
Intra-tumoral expression of the serine hydrolase carboxylesterase 2 (CES2) contributes to the activation of the pro-drug irinotecan in pancreatic ductal adenocarcinoma (PDAC). Given other potential roles of CES2, we assessed its regulation, downstream effects, and contribution to tumor development in PDAC. Association between the mRNA expression of CES2 in pancreatic tumors and overall survival was assessed using The Cancer Genome Atlas. Cell viability, clonogenic, and anchorage-independent growth assays as well as an orthotopic mouse model of PDAC were used to evaluate the biological relevance of CES2 in pancreatic cancer. CES2-driven metabolic changes were determined by untargeted and targeted metabolomic analyses. Elevated tumoral CES2 mRNA expression was a statistically significant predictor of poor overall survival in PDAC patients. Knockdown of CES2 in PDAC cells reduced cell viability, clonogenic capacity, and anchorage-independent growth in vitro and attenuated tumor growth in an orthotopic mouse model of PDAC. Mechanistically, CES2 was found to promote the catabolism of phospholipids resulting in HNF4α activation through a soluble epoxide hydrolase (sEH)-dependent pathway. Targeting of CES2 via siRNA or small molecule inhibitors attenuated HNF4α protein expression and reduced gene expression of classical/progenitor markers and increased basal-like markers. Targeting of the CES2-sEH-HNF4α axis using small molecule inhibitors of CES2 or sEH reduced cell viability. We establish a novel regulatory loop between CES2 and HNF4α to sustain the progenitor subtype and promote PDAC progression and highlight the potential utility of CES2 or sEH inhibitors for the treatment of PDAC as part of non-irinotecan-containing regimens.

20 May 2009 in Wound Repair and Regeneration
Verified
Journal Article
Open access
PDF file
Richard H GomerRichard H Gomer
Richard H Gomer
DPDarrell Pilling
Darrell Pilling
LKLawrence Kauvar
Lawrence Kauvar
SEStote Ellsworth
Stote Ellsworth
SRSanna D. Ronkainen
Sanna D. Ronkainen
SDStephen C. Davis
Stephen C. Davis
During wound healing, some circulating monocytes enter the wound, differentiate into fibroblast‐like cells called fibrocytes, and appear to then further differentiate into myofibroblasts, cells that play a key role in collagen deposition, cytokine release, and wound contraction. The differentiation of monocytes into fibrocytes is inhibited by the serum protein serum amyloid P (SAP). Depleting SAP at a wound site thus might speed wound healing. SAP binds to some types of agarose in the presence of Ca2+. We found that human SAP binds to an agarose with a KD of 7 × 10−8 M and a Bmax of 2.1 μg SAP/mg wet weight agarose. Mixing this agarose 1 : 5 w/v with 30 μg/mL human SAP (the average SAP concentration in normal serum) in a buffer containing 2 mM Ca2+ reduced the free SAP concentration to ∼0.02 μg/mL, well below the concentration that inhibits fibrocyte differentiation. Compared with a hydrogel dressing and a foam dressing, dressings containing this agarose and Ca2+ significantly increased the speed of wound healing in partial thickness wounds in pigs. This suggests that agarose/Ca2+ dressings may be beneficial for wound healing in humans.

1 November 2020 in JCO Precision Oncology
Verified
Journal Article
Open access
MCMichela Capello
Michela Capello
JFJohannes Fahrmann
Johannes Fahrmann
MPMayrim V. Rios Perez
Mayrim V. Rios Perez
JVJody Vykoukal
Jody Vykoukal
EIEhsan Irajizad
Ehsan Irajizad
Samir M. HanashSamir M. Hanash
Samir M. Hanash
The combination chemotherapy of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has provided clinically meaningful improvement for pancreatic ductal adenocarcinoma (PDAC). We previously uncovered a role for the serine hydrolase carboxylesterase 2 (CES2) in mediating intratumoral activation of the prodrug irinotecan, a constituent of FOLFIRINOX. We aimed to further test the predictive value of CES2 for response to irinotecan using patient-derived xenograft (PDX) models and to elucidate the determinants of CES2 expression and response to FOLFIRINOX treatment among patients with PDAC. PDXs were engrafted subcutaneously into nude mice and treated for 4 weeks with either saline control or irinotecan. CES2 and hepatocyte nuclear factor 4 alpha (HNF4A) expression in PDAC tissues was evaluated by immunohistochemical and Western blot analysis. Kaplan-Meier and Cox regression analyses were applied to assess the association between overall survival and hemoglobin A1C (HbA1C) levels in patients who underwent neoadjuvant FOLFIRINOX treatment. High CES2 activity in PDAC PDXs was associated with increased sensitivity to irinotecan. Integrated gene expression, proteomic analyses, and in vitro genetic experiments revealed that nuclear receptor HNF4A, which is upregulated in diabetes, is the upstream transcriptional regulator of CES2 expression. Elevated CES2 protein expression in PDAC tissues was positively associated with a history of type 2 diabetes (odds ratio, 4.84; P = .02). High HbA1C levels were associated with longer overall survival in patients who received neoadjuvant FOLFIRINOX treatment (P = .04). To our knowledge, we provide, for the first time, evidence that CES2 expression is associated with a history of type 2 diabetes in PDAC and that elevated HbA1C, by predicting tumor CES2 expression, may represent a novel marker for stratifying patients most likely to respond to FOLFIRINOX therapy.

1 January 2017 in Seminars in Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
FBFarzaneh Banki
Farzaneh Banki
CKChandni Kaushik
Chandni Kaushik
DRDavid Roife
David Roife
KMKyle G. Mitchell
Kyle G. Mitchell
CMCharles C. Miller
Charles C. Miller

1 December 2016 in The American Journal of Surgery
Verified
Journal Article
Closed access
FBFarzaneh Banki
Farzaneh Banki
CKChandni Kaushik
Chandni Kaushik
DRDavid Roife
David Roife
MCMunish Chawla
Munish Chawla
RCRobert Casimir
Robert Casimir
CMCharles C. Miller
Charles C. Miller